# US 9,433,674 B2 · Composition comprising a colloidal synthetic bioresorbable vector and a viral vector

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,433,674 B2
- Document ID: US9433674B2
- Status: Granted
- Kind: B2
- Application number: 14/620,920
- Filed: 2015-02-12
- Published: 2015-06-04
- Granted: 2016-09-06
- Earliest claimed: 2005-11-14
- Assignees: Centre Nationale De Recherche Scientifique
- Applicants: Centre National De La Recherche Scientifique
- Inventors: Yasemin Ataman-Onal; Thierry Delair; Bernard Verrier
- Web page: https://patentgrep.com/patent/US9433674B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/0011: {Cancer antigens}
- A61K 39/12: Viral antigens
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/235: Adenoviridae
- A61K 39/285: Vaccinia virus or variola virus
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 47/6905: {the form being a colloid or an emulsion}
- A61K 47/6921: {the form being a particulate, a powder, an adsorbate, a bead or a sphere}
- A61K 47/6927: {the form being a solid microparticle having no hollow or gas-filled cores}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55583: {Polysaccharides}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- A61K 2039/6087: {Polysaccharides; Lipopolysaccharides [LPS]}
- A61K 2039/6093: {Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine}
- C12N 2710/10041: Use of virus, viral particle or viral elements as a vector
- C12N 2710/10071: Demonstrated in vivo effect
- C12N 2710/10343: viral genome or elements thereof as genetic vector
- C12N 2710/24141: Use of virus, viral particle or viral elements as a vector
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- C12N 2710/24171: Demonstrated in vivo effect
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16071: Demonstrated in vivo effect
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of vaccination against a viral, bacterial or non-infectious disease includes administering an effective dose of a prime vaccine and then an effective dose of a boost vaccine. Each one of the prime vaccine and the boost vaccine includes an active principle. The prime vaccine includes, as the active principle, a colloidal synthetic bioresorbable vector that includes at least one protein substance. The boost vaccine includes, as the active principle, a viral vector that includes at least one nucleotide sequence which codes for a protein substance corresponding to the at least one protein substance of the synthetic vector.

## Claims

### Claim 1

A method of vaccination against a viral, bacterial or non-infectious disease comprising administering an effective dose of a prime vaccine and then an effective dose of a boost vaccine, each one of the prime vaccine and the boost vaccine comprising an active principle, wherein:
the prime vaccine comprises, as the active principle, a colloidal synthetic bioresorbable vector comprising at least one protein substance attached to a synthetic vector by inclusion or bonding; and
the boost vaccine comprises, as the active principle, a viral vector comprising at least one nucleotide sequence which codes for a protein substance corresponding to the at least one protein substance of the colloidal synthetic bioresorbable vector.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector is a vector of spherical nature.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector is prepared from at least one polymer selected from the group consisting of poly(a-hydroxy acids), polyhydroxybutyric acids, polycaprolactones, polyorthoesters, and polyanhydrides.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the polymer is selected from the group consisting of poly(D-lactic acid), poly(L-lactic acid), polyglycolic acid, a mixture of poly(D- and L-lactic acids), a mixture of poly(L-lactic acid) and polyglycolic acid, a mixture of poly(O-lactic acid) and polyglycolic acid, and a mixture of poly(D- and L-lactic acids) and polyglycolic acid.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector is prepared from at least one natural polymer.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the natural polymer is selected from the group consisting of hyaluronic acid, chitosan and dextran.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector comprises protein substances of different types, each constituting an antigen associated with the same disease.

### Claim 8 (depends on 1)

The method according to the claim 1, wherein the viral vector is an adenovirus or a poxvirus.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the viral vector is a Modified Vaccinia Virus Ankara.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the viral vector is the adenovirus 5.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the protein substances are of viral origin.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the protein substances of viral origin are proteins from a virus selected from the group consisting of herpes viruses, hepatitis viruses, papilloma viruses (HPV), human immunodeficiency viruses (IV), human influenza viruses, and avian influenza viruses.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the protein substance is an antigen associated with tumours.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector has a submicron size.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector has a diameter between 150 and 900 nm.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector has a diameter between 250 and 700 nm.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the colloidal synthetic bioresorbable vector is free of stabilizer and surfactant.

### Claim 18 (depends on 1)

The method according to claim 1, further comprising administering an additional dose of the prime vaccine before the boost vaccine is administered.